Literature DB >> 21868039

Dopaminergic dysregulation syndrome in Parkinson's disease.

Regina Katzenschlager1.   

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative condition which requires gradually increasing doses of dopaminergic substances for adequate motor control. Some vulnerable patients increase their doses beyond those required for motor control. This may result in a pattern of compulsive drug taking which may be associated with typical behavioural changes which define dopaminergic dysregulation syndrome (DDS). This is frequently associated with impulse control disorders and a specific behavioural abnormality involving prolonged repetitive tasks, called punding. The pathophysiology of DDS likely involves a number of factors, including genetic and personality related risk factors, habit formation resulting from unpleasant OFF symptoms, fronto-striatal dysfunction and a sensitisation process due to repeated dopaminergic stimulation. Management includes attempts to reduce the dopaminergic dose; specific treatment options are currently unknown. Early detection and prevention are therefore essential.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21868039     DOI: 10.1016/j.jns.2011.07.012

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  14 in total

Review 1.  New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson's disease.

Authors:  Giacomo Grassi; Giovanni Albani; Federica Terenzi; Lorenzo Razzolini; Silvia Ramat
Journal:  Neurol Sci       Date:  2021-04-14       Impact factor: 3.307

Review 2.  Substance of abuse and movement disorders: complex interactions and comorbidities.

Authors:  Andres Deik; Rachel Saunders-Pullman; Marta San Luciano
Journal:  Curr Drug Abuse Rev       Date:  2012-09

Review 3.  Sex, drugs and Parkinson's disease.

Authors:  Mwiza Ushe; Joel S Perlmutter
Journal:  Brain       Date:  2013-02       Impact factor: 13.501

4.  Crack cocaine use due to dopamine agonist therapy in Parkinson disease.

Authors:  Joseph H Friedman; Victoria Chang
Journal:  Neurology       Date:  2013-05-15       Impact factor: 9.910

5.  Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.

Authors:  Ashok Sriram; Herbert E Ward; Anhar Hassan; Sanjay Iyer; Kelly D Foote; Ramon L Rodriguez; Nikolaus R McFarland; Michael S Okun
Journal:  J Neurol       Date:  2012-09-25       Impact factor: 4.849

6.  Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias.

Authors:  Jared T Hinkle; Kate Perepezko; Liana S Rosenthal; Kelly A Mills; Alexander Pantelyat; Zoltan Mari; Laura Tochen; Jee Yun Bang; Medha Gudavalli; Nadine Yoritomo; Ankur Butala; Catherine C Bakker; Vanessa Johnson; Emile Moukheiber; Ted M Dawson; Gregory M Pontone
Journal:  Parkinsonism Relat Disord       Date:  2017-11-21       Impact factor: 4.891

7.  The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study.

Authors:  Pedro Barbosa; Atbin Djamshidian; Andrew J Lees; Thomas T Warner
Journal:  Mov Disord Clin Pract       Date:  2018-10-04

8.  Advanced Therapies for the Management of Dopamine Dysregulation Syndrome in Parkinson's Disease.

Authors:  Sanskriti Sasikumar; Roberto Matta; Renato P Munhoz; Mateusz Zurowski; Yu-Yan Poon; Mojgan Hodaie; Suneil K Kalia; Andres M Lozano; Alfonso Fasano
Journal:  Mov Disord Clin Pract       Date:  2021-03-11

9.  Attentional dysfunction and the punding spectrum in Parkinson's disease.

Authors:  Jared T Hinkle; Kate Perepezko; Kelly A Mills; Gregory M Pontone
Journal:  Parkinsonism Relat Disord       Date:  2021-01-30       Impact factor: 4.891

10.  Dopamine dysregulation syndrome and deep brain stimulation of the subthalamic nucleus in Parkinson's disease.

Authors:  Beatriz De la Casa-Fages; Francisco Grandas
Journal:  Neurol Res Int       Date:  2011-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.